Ignite Creation Date:
2024-05-05 @ 11:12 PM
Last Modification Date:
2024-10-26 @ 10:29 AM
Study NCT ID:
NCT01271101
Status:
UNKNOWN
Last Update Posted:
2011-01-06
First Post:
2011-01-05
Brief Title:
The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome
Status:
UNKNOWN
Status Verified Date:
2010-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EASY-CHINA
Brief Summary:
The primary objective of the EASY-CHINA Registry is to describe the clinical epidemiology of Chinese patients with NSTE-ACS to evaluate their current anticoagulation management in China and the resources used for it
Detailed Description:
Non-ST-elevated acute coronary syndromes NSTE-ACSare the leading cause of emergency medical care in the USA In China these syndromes have also become the major causes of morbidity and mortality and account for several thousands of death and hospitalizations annually Anti-platelet drugs anticoagulants and intervention therapy for high-risk NSTE-ACS patients may increase bleeding events while reducing ischemic coronary events There are some evidences supporting the association between hemorrhagic complications and short- and long-term mortality Therefore future advances in antithrombotic therapy for NSTE-ACS need to focus on reducing ischemic event rates without increasing hemorrhagic complication rates In this general framework there is the need for an appropriate adoption of the available evidences concerning therapeutic strategies specifically the use of the different antithrombotic strategies in real world patients in order to further improve their outcomesThe primary objective of this study is to describe the clinical epidemiology of Chinese patients with NSTE-ACS and to evaluate their current management in China This study will be an observational survey thus zero interference is emphasized throughout it No randomization blinding or special treatment will be assigned for the subjects Issues concerning the care of subjects are completely left to the discretion of investigators in order to collect the real-world information about the pharmacological treatments for NSTE-ACS patients in china
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None